259 related articles for article (PubMed ID: 12024032)
21. Fusion tyrosine kinases: a result and cause of genomic instability.
Penserga ET; Skorski T
Oncogene; 2007 Jan; 26(1):11-20. PubMed ID: 16785987
[TBL] [Abstract][Full Text] [Related]
22. Complementary functions of the antiapoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis.
Nieborowska-Skorska M; Hoser G; Kossev P; Wasik MA; Skorski T
Blood; 2002 Jun; 99(12):4531-9. PubMed ID: 12036885
[TBL] [Abstract][Full Text] [Related]
23. Activation of the NF-kappaB pathway by the leukemogenic TEL-Jak2 and TEL-Abl fusion proteins leads to the accumulation of antiapoptotic IAP proteins and involves IKKalpha.
Malinge S; Monni R; Bernard O; Penard-Lacronique V
Oncogene; 2006 Jun; 25(25):3589-97. PubMed ID: 16434962
[TBL] [Abstract][Full Text] [Related]
24. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
25. DNA double-strand break repair signalling: the case of RAD51 post-translational regulation.
Daboussi F; Dumay A; Delacôte F; Lopez BS
Cell Signal; 2002 Dec; 14(12):969-75. PubMed ID: 12359302
[TBL] [Abstract][Full Text] [Related]
26. Bcl-XL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo.
Coluccia AM; Perego S; Cleris L; Gunby RH; Passoni L; Marchesi E; Formelli F; Gambacorti-Passerini C
Blood; 2004 Apr; 103(7):2787-94. PubMed ID: 14656879
[TBL] [Abstract][Full Text] [Related]
27. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.
Dai Y; Rahmani M; Corey SJ; Dent P; Grant S
J Biol Chem; 2004 Aug; 279(33):34227-39. PubMed ID: 15175350
[TBL] [Abstract][Full Text] [Related]
28. Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells.
Ruchatz H; Coluccia AM; Stano P; Marchesi E; Gambacorti-Passerini C
Exp Hematol; 2003 Apr; 31(4):309-15. PubMed ID: 12691918
[TBL] [Abstract][Full Text] [Related]
29. Differences in BCL-X(L) expression and STAT5 phosphorylation in chronic myeloid leukaemia patients.
Gutiérrez-Castellanos S; Cruz M; Rabelo L; Godínez R; Reyes-Maldonado E; Riebeling-Navarro C
Eur J Haematol; 2004 Apr; 72(4):231-8. PubMed ID: 15089759
[TBL] [Abstract][Full Text] [Related]
30. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
31. BLM helicase is activated in BCR/ABL leukemia cells to modulate responses to cisplatin.
Slupianek A; Gurdek E; Koptyra M; Nowicki MO; Siddiqui KM; Groden J; Skorski T
Oncogene; 2005 Jun; 24(24):3914-22. PubMed ID: 15750625
[TBL] [Abstract][Full Text] [Related]
32. Haemopoietic transformation by the TEL/ABL oncogene.
Hannemann JR; McManus DM; Kabarowski JH; Wiedemann LM
Br J Haematol; 1998 Jul; 102(2):475-85. PubMed ID: 9695962
[TBL] [Abstract][Full Text] [Related]
33. FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).
Bagrintseva K; Geisenhof S; Kern R; Eichenlaub S; Reindl C; Ellwart JW; Hiddemann W; Spiekermann K
Blood; 2005 May; 105(9):3679-85. PubMed ID: 15626738
[TBL] [Abstract][Full Text] [Related]
34. Bcl-2-independent Bcr-Abl-mediated resistance to apoptosis: protection is correlated with up regulation of Bcl-xL.
Amarante-Mendes GP; McGahon AJ; Nishioka WK; Afar DE; Witte ON; Green DR
Oncogene; 1998 Mar; 16(11):1383-90. PubMed ID: 9525737
[TBL] [Abstract][Full Text] [Related]
35. Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways.
Kirito K; Watanabe T; Sawada K; Endo H; Ozawa K; Komatsu N
J Biol Chem; 2002 Mar; 277(10):8329-37. PubMed ID: 11756417
[TBL] [Abstract][Full Text] [Related]
36. The new iodoacetamidobenzofuran derivative TR120 decreases STAT5 expression and induces antitumor effects in imatinib-sensitive and imatinib-resistant BCR-ABL-expressing leukemia cells.
Grimaudo S; Meli M; Di Cristina A; Ferro A; Pipitone MR; Romagnoli R; Simoni D; Dieli F; Tolomeo M
Anticancer Drugs; 2013 Apr; 24(4):384-93. PubMed ID: 23370613
[TBL] [Abstract][Full Text] [Related]
37. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
38. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
39. Constitutive 53BP1/γH2AX foci are increased in cells of ALL patients dependent on BCR-ABL and TEL-AML1 preleukemic gene fusions.
Somsedikova A; Markova E; Kolenova A; Puskacova J; Kubes M; Belyaev I
Neoplasma; 2014; 61(5):617-25. PubMed ID: 25244981
[TBL] [Abstract][Full Text] [Related]
40. Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells.
Nieborowska-Skorska M; Slupianek A; Xue L; Zhang Q; Raghunath PN; Hoser G; Wasik MA; Morris SW; Skorski T
Cancer Res; 2001 Sep; 61(17):6517-23. PubMed ID: 11522649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
